Immunotherapy in HCC: A 2025 Expert Update

Immunotherapy in HCC: A 2025 Expert Update

1. Evolving First-Line Standards

• The combination of atezolizumab + bevacizumab remains a cornerstone first-line regimen for unresectable HCC. In the landmark IMbrave150 trial, this duo significantly improved median overall survival (19.2 vs. 13.4 months) and progression-free survival compared to sorafenib. (Gastroenterology and Hepatology)

• The STRIDE regimen—tremelimumab (anti‑CTLA‑4) plus durvalumab (anti‑PD‑L1)—showed a 48‑month overall survival rate of 25.2% vs. 15.1% with sorafenib. ASCO now strongly recommends either atezolizumab/bevacizumab or this dual ICI combination for CP-A advanced HCC. (Gastroenterology and Hepatology)

2. Combination Therapies & Locoregional Integration

• Adding immunotherapy to TACE is emerging as a promising approach for intermediate-stage HCC. Trials like LEAP‑012 (TACE + pembrolizumab + lenvatinib) and EMERALD‑1 (TACE + durvalumab + bevacizumab) reported meaningful improvements in progression-free survival (14.6 vs. 10 months, and 15 vs. 8.2 months respectively). (Cancer.gov)

3. Adjuvant & Post-Surgical Immunotherapy Innovations

• The IMbrave050 trial tested adjuvant atezolizumab + bevacizumab after resection or ablation. However, updated guidance from AASLD notes that recurrence-free survival benefits were not sustained, and overall survival remains nonsignificantly improved—suggesting this combination should not be used routinely post-surgery. (Lippincott Journals)

• Exciting developments in adoptive immune-cell therapy—including CAR‑T cells, cytokine-induced killer cells, and liver-resident NK-cell approaches—are under investigation to reduce recurrence post-resection or transplantation. (PubMed)

4. Beyond Checkpoint Inhibitors: Next-Gen Strategies

• Reviews highlight that while PD‑1/PD‑L1 inhibitors opened the immunotherapy era, emerging modalities now include cytokine-based therapies, oncolytic viruses, and adoptive cellular therapies as part of multi-pronged strategies against HCC. (SpringerLink)

• Novel antibody-based approaches—like bispecific antibodies and antibody–drug conjugates (ADCs) that target specific antigens such as glypican‑3—are gaining traction for their precision. (Frontiers)

• Future targets like TIM‑3, TIGIT, and cytokines such as IL‑27, plus novel combos (e.g., FGFR4 inhibition with atezolizumab), show early promise in shaping future clinical trials. (VJOncology)

5. Personalized Vaccines & Overcoming Resistance

• A groundbreaking early trial using a personalized neoantigen DNA vaccine combined with pembrolizumab (Keytruda) achieved tumor shrinkage in ~30% of advanced HCC patients and three complete responses—about double responses seen with immunotherapy alone. (reuters.com)

• HCC’s immunosuppressive microenvironment—such as CD19⁺ macrophage populations that express PD‑L1 and CD73—can hinder therapy. Preclinical data show that targeting these macrophages (e.g., via anti-CD19 CAR‑T) or inhibiting CD73 improves checkpoint blockade efficacy. (arXiv)

Summary Table: Key Immunotherapy Advances in HCC

Why This Matters for Dr. Chetan Kalal’s Practice

• Positions him at the forefront of emerging HCC care—leading with combination immunotherapy and world-class diagnostic insight (e.g., fibroscan, transplant decision-making).

• Bolsters his credibility in managing complex cases—including decisions around adjuvant therapy, transplant timing, or TACE combinations.

• Supports patient education and global consultations, reinforcing his role as an informed, up-to-date authority in hepatology.